These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29181714)

  • 1. Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?
    Wynberg E; Williams E; Tudor-Williams G; Lyall H; Foster C
    Clin Drug Investig; 2018 Mar; 38(3):231-238. PubMed ID: 29181714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.
    BREATHER (PENTA 16) Trial Group
    Lancet HIV; 2016 Sep; 3(9):e421-e430. PubMed ID: 27562743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
    Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R
    JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
    Sonenthal PD; Ratshaa B; Chimbengo G; Rantleru T; Ngoni T; Barenbaum S; Platoff R; Steenhoff AP; Gross R
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):773-7. PubMed ID: 24664872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
    Cressey TR; Green H; Khoo S; Treluyer JM; Compagnucci A; Saidi Y; Lallemant M; Gibb DM; Burger DM;
    Clin Infect Dis; 2008 May; 46(10):1601-8. PubMed ID: 18419497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
    J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India.
    Dravid A; Betha TP; Sharma AK; Gawali R; Mahajan U; Kulkarni M; Saraf C; Kore S; Dravid M; Rathod N
    HIV Med; 2020 Oct; 21(9):578-587. PubMed ID: 33021066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Penazzato M; Giaquinto C
    Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
    European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
    Clin Infect Dis; 2018 Feb; 66(4):594-603. PubMed ID: 29029056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
    Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
    AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
    Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
    Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
    Turkova A; Moore CL; Butler K; Compagnucci A; Saïdi Y; Musiime V; Nanduudu A; Kaudha E; Cressey TR; Chalermpantmetagul S; Scott K; Harper L; Montero S; Riault Y; Bunupuradah T; Volokha A; Flynn PM; Bologna R; Ramos Amador JT; Welch SB; Nastouli E; Klein N; Giaquinto C; Ford D; Babiker A; Gibb DM;
    PLoS One; 2018; 13(4):e0196239. PubMed ID: 29684092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    Kekitiinwa A; Szubert AJ; Spyer M; Katuramu R; Musiime V; Mhute T; Bakeera-Kitaka S; Senfuma O; Walker AS; Gibb DM;
    Pediatr Infect Dis J; 2017 Jun; 36(6):588-594. PubMed ID: 28505015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
    Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
    BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.